{"041.SG": {"short_name": "ADL Bionatur Solutions S.A. Acc", "long_name": "ADL Bionatur Solutions, S.A.", "summary": "ADL Bionatur Solutions, S.A. engages in the research, development, manufacturing, and commercialization of products in biotech and pharmaceutical industry in Spain. It provides solutions in health, nutrition, cosmetics, and materials. The company was founded in 1954 and is headquartered in C\u00c3\u00a1diz, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STU", "market": "dr_market", "country": "Spain", "city": "C\u00c3\u00a1diz"}, "ADL.MC": {"short_name": "ADL BIONATUR SOLUTIONS, S.A.", "long_name": "ADL Bionatur Solutions, S.A.", "summary": "ADL Bionatur Solutions, S.A. engages in the research, development, manufacturing, and commercialization of products in biotech and pharmaceutical industry in Spain. It provides solutions in health, nutrition, cosmetics, and materials. The company was founded in 1954 and is headquartered in C\u00c3\u00a1diz, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "C\u00c3\u00a1diz"}, "ALM.MC": {"short_name": "ALMIRALL S.A.", "long_name": "Almirall, S.A.", "summary": "Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. It also has a strategic partnership with Tyris Therapeutics to develop gene therapies for the treatment of rare genetic dermatology diseases. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Barcelona"}, "ATRY.MC": {"short_name": "ATRYS HEALTH, S.A.", "long_name": "Atrys Health, S.A.", "summary": "Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. The company also provides radiotherapy; and develops therapeutic modalities and diagnostic tools. Atrys Health, S.A. was founded in 2007 and is based in Barcelona, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Barcelona"}, "BIO.MC": {"short_name": "BIOSEARCH, S.A.", "long_name": "Biosearch, S.A.", "summary": "Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Granada"}, "CBAV.MC": {"short_name": "CLINICA BAVIERA S.A.", "long_name": "Cl\u00ednica Baviera, S.A.", "summary": "Cl\u00c3\u00adnica Baviera, S.A. operates a network of ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. The company's clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, oculoplasty, cornea, neuroftalmolog\u00c3\u00ada, and vias lagrimales treatments, as well as refractive surgery services. It operates approximately 80 ophthalmological clinics in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Madrid"}, "D9Z.F": {"short_name": "CLINICA BAVIERA SA EO-,10", "long_name": "Cl\u00ednica Baviera, S.A.", "summary": "Cl\u00c3\u00adnica Baviera, S.A. operates a network of ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. The company's clinics offers myopia, hyperopia, astigmatism, presbyopia, cataract, retina, pediatric ophthalmology, glaucoma, squint, oculoplasty, cornea, neuroftalmolog\u00c3\u00ada, and vias lagrimales treatments, as well as refractive surgery services. It operates approximately 80 ophthalmological clinics in Spain, Germany, Austria, and Italy. The company is based in Madrid, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "FRA", "market": "dr_market", "country": "Spain", "city": "Madrid"}, "E2Z.F": {"short_name": "ALMIRALL S.A.  EO -,12", "long_name": "Almirall, S.A.", "summary": "Almirall, S.A., a pharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines worldwide. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, cutaneous T-cell lymphoma, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications; and for central nervous system, cardiovascular, and gastrointestinal diseases. Its products include Actikerall, Solaraze, Cordran Tape, Skilarence, Ilumetri, Seysara, Almax, Crestor, Provisacor, Sativex, Ebastel, Aczone, Tazorac, Azelex, and Veltin. Almirall, S.A. has a strategic research collaboration with Evotec AG to discover and develop first-in-class therapeutics in the field of dermatology diseases; collaborative research and license agreement with X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases; research collaboration with Iktos in the area of artificial intelligence for new drug design; multi-target research collaboration with the University of Dundee to develop novel targeted protein degraders medicines; and collaboration with Popit to provide a novel support solution for patients with psoriasis. It also has a strategic partnership with Tyris Therapeutics to develop gene therapies for the treatment of rare genetic dermatology diseases. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Spain", "city": "Barcelona"}, "EEP.MC": {"short_name": "EUROESPES, S.A.", "long_name": "Euroespes, S.A.", "summary": "Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as digital diagnosis, neuro-psychology, neuro-otolaryngology, neuro-ophthalmology, nursing, radioa diagnosis, and laboratory services. In addition, it offers pharmacogenetic cards; biotechnology; and a range of nutraceuticals. The company was founded in 1991 and is based in Corunna, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Corunna"}, "FAE.MC": {"short_name": "FAES FARMA, S.A.", "long_name": "Faes Farma, S.A.", "summary": "Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Leioa"}, "FEQ1.F": {"short_name": "LABORATORIO REIG J.EO 0,5", "long_name": "Laboratorio Reig Jofre, S.A.", "summary": "Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Fort\u00c3\u00a9 Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Desp\u00c3\u00ad, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Spain", "city": "Barcelona"}, "FFEA.F": {"short_name": "FAES FARMA INH.  EO-,10", "long_name": "Faes Farma, S.A.", "summary": "Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "FRA", "market": "dr_market", "country": "Spain", "city": "Leioa"}, "G0FB.F": {"short_name": "GRIFOLS SP.ADR B EO-,10 1", "long_name": "Grifols, S.A.", "summary": "Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "FRA", "market": "dr_market", "country": "Spain", "city": "Barcelona"}, "GIFLF": {"short_name": "GRIFOLS SA", "long_name": "Grifols, S.A.", "summary": "Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "PNK", "market": "us_market", "country": "Spain", "city": "Barcelona"}, "GIKLY": {"short_name": "GRIFOLS SA", "long_name": "Grifols, S.A.", "summary": "Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "PNK", "market": "us_market", "country": "Spain", "city": "Barcelona"}, "GRF.MC": {"short_name": "GRIFOLS S.A.", "long_name": "Grifols, S.A.", "summary": "Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Barcelona"}, "GRF.VI": {"short_name": "GRIFOLS SA", "long_name": "Grifols, S.A.", "summary": "Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "VIE", "market": "at_market", "country": "Spain", "city": "Barcelona"}, "GRFS": {"short_name": "Grifols, S.A.", "long_name": "Grifols, S.A.", "summary": "Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "NMS", "market": "us_market", "country": "Spain", "city": "Barcelona"}, "MED.MC": {"short_name": "MEDCOM TECH, S.A.", "long_name": "Medcomtech, S.A.", "summary": "Medcomtech, S.A. distributes products in the areas of orthopedic surgery, traumatology, neurosurgery, and anesthesia worldwide. The company offers orthopedic surgery, trauma, and neurosurgery products for spine, hip-femur-knee, biologics, and upper and lower limbs, as well as biologics and cements. It also provides anesthesia products in the area of airway management. The company was founded in 2001 and is based in Barcelona, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Medical Distribution", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Barcelona"}, "ORN.F": {"short_name": "ORYZON GENOMICS SA EO-,05", "long_name": "Oryzon Genomics S.A.", "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in Cornell\u00c3\u00a0 de Llobregat, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Spain", "city": "Cornell\u00c3\u00a0 de Llobregat"}, "ORY.MC": {"short_name": "ORYZON GENOMICS, S.A.", "long_name": "Oryzon Genomics S.A.", "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in Cornell\u00c3\u00a0 de Llobregat, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Cornell\u00c3\u00a0 de Llobregat"}, "ORYZF": {"short_name": "ORYZON GENOMICS SA", "long_name": "Oryzon Genomics S.A.", "summary": "Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for the treatment of oncological and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, a LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases, as well as other programs at various stages of development. The company was founded in 2000 and is based in Cornell\u00c3\u00a0 de Llobregat, Spain.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Spain", "city": "Cornell\u00c3\u00a0 de Llobregat"}, "OZTA.F": {"short_name": "GRIFOLS SA INH. A  EO-,25", "long_name": "Grifols, S.A.", "summary": "Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates in five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products. It offers intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. has a technology collaboration agreement with Mondragon; and a formal collaboration with the United States Biomedical Advanced Research Development Authority, the Food and Drug Administration, and other Federal public health agencies. The company was founded in 1940 and is headquartered in Barcelona, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "FRA", "market": "dr_market", "country": "Spain", "city": "Barcelona"}, "PANG.MC": {"short_name": "PANGAEA ONCOLOGY S.A.", "long_name": "Pangaea Oncology, S.A.", "summary": "Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients, and pharmaceutical and biotech clients worldwide. It offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, Western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. The company also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2007 and is based in Barcelona, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Diagnostics & Research", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Barcelona"}, "PHM.MC": {"short_name": "PHARMA MAR, S.A.", "long_name": "Pharma Mar, S.A.", "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Madrid"}, "PHMMF": {"short_name": "PHARMA MAR SA", "long_name": "Pharma Mar, S.A.", "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Spain", "city": "Madrid"}, "PMRA.F": {"short_name": "PHARMA MAR S.A. EO -,60", "long_name": "Pharma Mar, S.A.", "summary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was founded in 1986 and is based in Madrid, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Spain", "city": "Madrid"}, "PUL.F": {"short_name": "BIOSEARCH S.A.INH. EO-,24", "long_name": "Biosearch, S.A.", "summary": "Biosearch, S.A., a biotechnology company, operates in pharmaceutical, nutraceutical, and functional food sectors worldwide. It offers a portfolio of approximately 200 products in lipids, probiotics, and botanical extracts. The company provides a range of probiotics isolated from human breast milk under the Hereditum brand for use in infant nutrition, gastrointestinal health, and immune system and prevention of infections. It also offers various eicosapentaenoic acid and docosahexaenoic acid rich ingredients under the Eupoly-3 name, which consists of oils, emulsions, and micro-encapsulated powder for functional foods, primarily dairy products, baby foods, medical foods, and food supplements. In addition, the company provides dry, fluid, glycerinated, and soft extracts under the Exxentia name. Biosearch, S.A. is headquartered in Granada, Spain.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Spain", "city": "Granada"}, "RJF.MC": {"short_name": "LABORATORIO REIG JOFRE, S.A.", "long_name": "Laboratorio Reig Jofre, S.A.", "summary": "Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include pharmaceutical technologies products, such as antibiotics, and injectable and other products; specialty pharmacare products, which include skin, hair, and nail health, joint health and pain, women's health, respiratory/ENT, and pediatrics; and consumer healthcare products under the Fort\u00c3\u00a9 Pharma brand. The company also provides CDMO and CMO services. It sells its products directly in 7 countries and through business partners in approximately 70 countries. The company was founded in 1929 and is based in Sant Joan Desp\u00c3\u00ad, Spain. Laboratorio Reig Jofre, S.A. is a subsidiary of Reig Jofre Investments SL.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014Specialty & Generic", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Barcelona"}, "ROVI.MC": {"short_name": "LABORATORIOS FARMACEUTICOS ROVI", "long_name": "Laboratorios Farmaceuticos Rovi, S.A.", "summary": "Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company also distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent thromboembolic disease; Enoxaparin biosimilar, a low-molecular-weight heparin; Neparvis for the treatment of symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for the treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebr\u00c3\u00a1n that are prescription medicines for treatment of attention deficit hyperactivity disorder in children and adolescents. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Expr\u00c3\u00a8s that are contrast injection systems and compatible disposable material. In addition, it provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing COVID-19 vaccine candidate. Laboratorios Farmaceuticos Rovi, S.A. was founded in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmace\u00c3\u00baticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "MCE", "market": "es_market", "country": "Spain", "city": "Madrid"}}